ArticlePharmacological reports : PR2026
Docosahexaenoic acid modulates myo-inositol and myo-inositol biosynthetic genes expression: implications for bipolar disorder.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBipolar disorder (BD) is a mood disorder affecting approximately 1–2% of the population. It is treated primarily with mood stabilizers, which have variable efficacy and tolerability. Omega-3 polyunsaturated fatty acids, particularly docosahexaenoic acid (DHA), have emerged as potential adjunctive treatments, though clinical findings and underlying mechanisms remain inconsistent. Given that myo-inositol depletion is proposed as a common mechanism for conventional mood stabilizers, we hypothesized that DHA, which modulates components of the phosphatidylinositol pathway, would alter intracellular myo-inositol and thus modulate myo-inositol homeostasis. The aim of this study was to determine the effect of DHA on intracellular myo-inositol and the expression of key genes involved in its biosynthesis.
methodsUsing an enzymatic assay, intracellular myo-inositol levels were measured in the extracts of cells grown in the presence of DHA. The effect of DHA on the expression of the myo-inositol biosynthetic genes INO1 (inositol-1-phosphate synthase) and INM1 (inositol monophosphatase) was assessed by RT-qPCR.
resultsDHA altered intracellular myo-inositol in a concentration-dependent manner, with low concentrations decreasing levels and higher concentrations producing increases relative to untreated controls. RT-qPCR analysis showed corresponding modulation of INO1 and INM1 expression, consistent with changes in myo-inositol homeostasis. While some group differences reached statistical significance, particularly in comparisons with valproate (VPA)-treated controls, most contrasts among DHA-treated groups were not significant.
conclusionThese findings provide preliminary evidence that DHA modulates intracellular myo-inositol levels and the expression of key biosynthetic genes in yeast. The biphasic response observed suggests a dose-sensitive effect that may help explain inconsistencies in clinical outcomes. While the results support the idea that omega-3 fatty acids influence inositol homeostasis, they should be considered hypothesis-generating and warrant confirmation in mammalian models and clinical settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41489728What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.